ClinicalTrials.gg
Not yet recruitingNCT07888985ALI-DOAKUpdated Oct 22, 2026

Changes in the Etiology of Acute Limb Ischemia in the DOAK Era

An observational study in Acute Limb Ischemia and Anticoagulants, sponsored by University Hospital Augsburg. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by University Hospital Augsburg · Observational

Updated Oct 22, 2026Newly registeredGo to Updates ↓
Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
400
Ages
18 Years and older
Sex
All
01

Study summary

This study therefore investigates whether the proportion of embolic acute limb ischemia in patients with atrial fibrillation changed significantly between the pre DOAK era (2006-2010) and the DOAK era (2012-2018) at a university vascular center

Read the detailed description

Retrospective data analysis of patients with acute limb ischemia and the change of etiology in the era of DOAK. The ICD includes both etiologies as embolic and thrombotic. Therefore recent analysis covered both etiologies as it's not possible to distinguish using ICD only. Aim of the study is a selection of those two etiologies.

02

Conditions studied

  • Acute Limb Ischemia
  • Anticoagulants

Browse trials for

Keywords

  • ALI
  • DOAK
  • acute limb ischemia
  • etiology
03

In context

Ischemia

545 studies on the registry are indexed under Ischemia; 72 are open to participants now.

This study's planned enrollment of 400 is above the median of 176 across 166 observational studies indexed under Ischemia.

Browse Ischemia studies →

Lead sponsor

University Hospital Augsburg is the lead sponsor of 25 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients with acute limb ischemia and atrial fibrillation.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Acute Limb Ischemia
  • atrial fibrillation

Exclusion criteria

Exclusion Criteria:

  • aortic dissection
  • iatrogenic ALI
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
400 participants (estimated)
Patient registry
No

Groups and cohorts

  • ALI with Anticoagulants

    Patients suffering form acute limb ischemia medicated with anticogulants

  • ALI without Anticoagulants

    Patients suffering form acute limb ischemia medicated without anticogulants

06

What researchers measure

Primary outcomes

  1. acute limb ischemia

    number of ALI patients. Method of measurement: Counting numbers, source: ICD-codes.

    Time frame: 01/2006 till 12/2018

Secondary outcomes

  1. etiology

    etiology of acute ischemia, either thrombotic or embolic. Method of measurement: manual selection of ICD-codes

    Time frame: 01/2006 till 12/2018

07

Study locations

No study locations are listed for this record.

08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — retrospective analysis

09

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07888985
Lead sponsor
University Hospital Augsburg
Responsible party
Yvonne Gosslau (MD, PhD, University Hospital Augsburg) — Principal investigator
First posted
Oct 22, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Oct 31, 2027 (estimated)
Completion
Oct 31, 2028 (estimated)
Last update
Oct 22, 2026

Study contacts

Yvonne N Goßlau
Contact
yvonne.gosslau@uk-augsburg.de
+49 821400161977
Claudia Weber
Contact
claudia.weber@uk-augsburg.de
+49 821 400 161933
Yvonne N Goßlau, MD, PhD
principal investigator · Vascular Surgery, Faculty of Medicine, University of Augsburg, Stenglinstr. 2, 86165 Augsburg, Germany

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion